Introduction
There are three fundamental steps that are necessary for the clinical management of a brain disorder: (1) detection and diagnosis; (2) treatment; and (3) assessment of treatment response. Neurodegenerative disorders are no exception; successful treatment requires prior detection and correct diagnosis. Drugs, surgical intervention, and behavioral therapy remain the major techniques used for treatment of brain disorders, and as a result, these become the targets for much of disease related scientific research. Although the efficacy of these interventions is important in individual patients and clinical trials, it may not always be measured with sensitive or relevant metrics, and therefore neuroscientific investigation addressing these topics remains very important. The fundamental argument made by all the articles in this special issue is that biomarkers will become an increasingly important component of the detection, diagnosis and assessment of treatment of neurodegenerative disorders. In this commentary we will focus on the roles that neuroimaging biomarkers can play, and discuss the advantages of the network paradigm in particular.
What can biomarkers be used for?
For a very long time, behavior was the primary source of information used for detection and diagnosis of neurodegenerative disorders. A person showed up at a clinician's office and complained of some neurological difficulty (e.g., poor memory, aberrant motor functioning). Observation plus some clinical tests were performed, and a preliminary diagnosis was provided. As time went by, the neurodegenerative disorder became worse and the diagnosis became firmer or perhaps changed. There are several problems with this traditional model. Patients often present relatively late when the underlying neuropathology is far advanced; e.g., striatal dopamine neuronal loss may exceed 90% before symptoms or diagnosis. Also, the same clinical phenotype may result from very different neuropathological processes; e.g., both tau and ubiquitin pathologies can cause the same clinical picture in frontotemporal dementia. Finally, common clinical measures such as the Mini Mental State Examination may be relatively insensitive to the beneficial effects of disease modifying therapies. Now, as the articles in this issue make clear, attempts are underway to develop biomarkers for many of the neurodegenerative disorders that have become major societal problems due to the increase in the number of aged individuals. Biomarkers come in four major flavors: blood, cerebrospinal fluid (CSF), genetic analysis and neuroimaging. As discussed by Hampel et al. (2010) for Alzheimer's disease (AD), there is not just one purpose for which a biomarker will be employed; rather, there are numerous and varied uses for which the development of biomarkers is crucial. The four major uses are (1) detection or prediction of a disorder, (2) the differential diagnosis of a disorder, (3) understanding the neural basis of the disorder, and (4) staging a This commentary provides a brief introduction to the various uses that functional neuroimaging biomarkers can play in detecting, diagnosing, assessing treatment response and investigating neurodegenerative disorders. It then goes on to explain why the emphasis of much recent work has shifted to network-based biomarkers, as opposed to those that examine individual brain regions. A number of examples are referenced that illustrate the points made.
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